ECSP099341A - Nuevos anticuerpos antiproliferativos - Google Patents

Nuevos anticuerpos antiproliferativos

Info

Publication number
ECSP099341A
ECSP099341A EC2009009341A ECSP099341A ECSP099341A EC SP099341 A ECSP099341 A EC SP099341A EC 2009009341 A EC2009009341 A EC 2009009341A EC SP099341 A ECSP099341 A EC SP099341A EC SP099341 A ECSP099341 A EC SP099341A
Authority
EC
Ecuador
Prior art keywords
antibodies
antiproliferative antibodies
relates
present
new antiproliferative
Prior art date
Application number
EC2009009341A
Other languages
English (en)
Inventor
Liliane Goetsch
Nathalie Corvaia
Jean-Francois Haeuw
Cedric Bes
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of ECSP099341A publication Critical patent/ECSP099341A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a nuevos anticuerpos aislados o los compuestos derivados o fragmentos funcionales de ello, capaces de inhibir la proliferación de células tumorales in vitro y/o in vivo, donde dichos anticuerpos fueron obtenidos por control funcional. Más en particular, la presente invención se refiere al anticuerpo 6F4, específico de la proteína JAM-A, así como a su uso para el tratamiento del cáncer. También están cubiertas las composiciones farmacéuticas compuestas por tales anticuerpos.
EC2009009341A 2006-11-24 2009-05-18 Nuevos anticuerpos antiproliferativos ECSP099341A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0610329A FR2909092B1 (fr) 2006-11-24 2006-11-24 Nouveaux anticorps anti-proliferation

Publications (1)

Publication Number Publication Date
ECSP099341A true ECSP099341A (es) 2009-06-30

Family

ID=37903981

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009341A ECSP099341A (es) 2006-11-24 2009-05-18 Nuevos anticuerpos antiproliferativos

Country Status (28)

Country Link
US (2) US8071730B2 (es)
EP (1) EP2074148A1 (es)
JP (1) JP2010509931A (es)
KR (1) KR20090088878A (es)
CN (1) CN101535344B (es)
AU (1) AU2007324509B2 (es)
BR (1) BRPI0719323A2 (es)
CA (1) CA2670039A1 (es)
CL (1) CL2007003357A1 (es)
CR (1) CR10788A (es)
CU (1) CU23792A3 (es)
EC (1) ECSP099341A (es)
FR (1) FR2909092B1 (es)
GE (1) GEP20125629B (es)
GT (1) GT200900126A (es)
HK (1) HK1132752A1 (es)
IL (1) IL198744A0 (es)
MA (1) MA30891B1 (es)
MX (1) MX2009005293A (es)
NI (1) NI200900079A (es)
NO (1) NO20092360L (es)
NZ (1) NZ576174A (es)
RU (1) RU2451689C2 (es)
SA (1) SA07280637B1 (es)
TN (1) TN2009000194A1 (es)
TW (1) TW200829602A (es)
UA (1) UA99602C2 (es)
WO (1) WO2008062063A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
WO2010002862A2 (en) * 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
AU2010313381A1 (en) * 2009-10-30 2012-04-12 Merck Sharp & Dohme Corp. AX1 and AX189 PCSK9 antagonists and variants
SG189929A1 (en) * 2010-10-29 2013-06-28 Immunogen Inc Novel egfr-binding molecules and immunoconjugates thereof
EP2455403A1 (en) 2010-11-23 2012-05-23 Pierre Fabre Medicament Homogeneous humanized antibodies against JAM-A that inhibit proliferation
US20130287790A1 (en) * 2012-03-30 2013-10-31 The Board Of Trustees Of The Leland Standford Junior University Use of jam-a in diagnosing and treating leukemia
CN109369808B (zh) 2012-08-24 2023-11-07 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
KR20150097304A (ko) 2014-02-18 2015-08-26 삼성전자주식회사 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체
BR112018067522A2 (pt) * 2016-03-01 2019-02-05 Univ Of Rijeka Faculty Of Medicine anticorpos específicos para receptor de poliovírus humano (pvr)
IL299099A (en) 2016-06-27 2023-02-01 Univ California Combinations of cancer treatments
WO2018027039A1 (en) * 2016-08-03 2018-02-08 Nextcure, Inc. Compositions and methods for modulating lair signal transduction
CN109022366A (zh) * 2018-08-16 2018-12-18 江南大学 一株分泌抗左旋咪唑单克隆抗体的杂交瘤细胞株及其应用
CN114740108B (zh) * 2022-03-28 2023-07-14 天津键凯科技有限公司 一种聚合物修饰抗体类药物的修饰度的测定方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604470D0 (sv) * 1996-12-04 1996-12-04 Tamas Bartfai Konsulting Ab Transmembrane component of tight junction
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20030171568A1 (en) * 1998-09-16 2003-09-11 Avi Ashkenazi Use of A33 antigens and JAM-IT
US6677436B1 (en) * 1998-04-03 2004-01-13 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
MXPA01009110A (es) * 1999-03-11 2002-08-20 Rmf Dictagene Sa Moleculas de adhesion vascular y modulacion de su funcion.
WO2005060457A2 (en) * 2003-12-04 2005-07-07 Pdl Biopharma, Inc. Treatment of inflammatory bowel diseases with anti-ip-10 antibodies
WO2006008076A2 (en) * 2004-07-16 2006-01-26 Universita Degli Studi Di Milano Methods and agents stimulating the immune response
WO2006121207A1 (en) * 2005-05-12 2006-11-16 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-dsc2 antibody
WO2007127476A2 (en) * 2006-04-28 2007-11-08 Oregon Health & Science University Monoclonal antibodies specific for pancreatic endocrine, exocrine or ductal cell

Also Published As

Publication number Publication date
US8071730B2 (en) 2011-12-06
NI200900079A (es) 2010-11-10
EP2074148A1 (en) 2009-07-01
AU2007324509A1 (en) 2008-05-29
JP2010509931A (ja) 2010-04-02
FR2909092A1 (fr) 2008-05-30
SA07280637B1 (ar) 2012-04-11
WO2008062063A1 (en) 2008-05-29
GEP20125629B (en) 2012-09-10
CN101535344A (zh) 2009-09-16
CL2007003357A1 (es) 2008-04-04
CN101535344B (zh) 2013-10-16
MX2009005293A (es) 2009-08-07
RU2009123409A (ru) 2010-12-27
CA2670039A1 (en) 2008-05-29
US20100092455A1 (en) 2010-04-15
CR10788A (es) 2009-06-23
GT200900126A (es) 2011-09-02
TW200829602A (en) 2008-07-16
HK1132752A1 (en) 2010-03-05
AU2007324509B2 (en) 2013-01-17
US20120156191A1 (en) 2012-06-21
BRPI0719323A2 (pt) 2014-02-04
RU2451689C2 (ru) 2012-05-27
CU23792A3 (es) 2012-03-15
TN2009000194A1 (en) 2010-10-18
NO20092360L (no) 2009-08-11
MA30891B1 (fr) 2009-11-02
FR2909092B1 (fr) 2012-10-19
UA99602C2 (ru) 2012-09-10
IL198744A0 (en) 2010-02-17
NZ576174A (en) 2012-03-30
KR20090088878A (ko) 2009-08-20

Similar Documents

Publication Publication Date Title
ECSP099341A (es) Nuevos anticuerpos antiproliferativos
CL2008000670A1 (es) Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras.
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
BRPI0710331A2 (pt) Compostos heteroarila monocíclicos para tratamento de câncer e composição
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
CL2007003774A1 (es) Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis.
AR085138A1 (es) VARIANTES DE Fc Y METODOS PARA SU PRODUCCION
DOP2011000199A (es) Compuestos heterociclocos y metodos de uso
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
CO6511271A2 (es) Compuestos de imidazopiridinil-aminopiridina sustituida
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
CR11200A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o p13k
CL2008001304A1 (es) Compuestos derivados de indol sustituido, inhibidores de la proteina activadora de la 5-lipoxigenasa (flap); composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, enfermedad cardiovascular e inflamacion.
CL2011002943A1 (es) Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica.
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
CL2008000348A1 (es) Compuestos derivados de carboxamida, inhibidores de la actividad de la proteina quinasa b; composicion farmaceutica; proceso para prepararla; y uso en el tratamiento de enfermedades tales como cancer y artritis.
CL2007003163A1 (es) Compuestos derivados de 5-oxo-5,8-dihidro-pirido-pirimidinas, inhibidores c-fms quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como epoc, asma, infeccion por vih, psoriasis, diabetes, obesidad y cancer de tumores s
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
CO6571881A2 (es) Nuevos anticuerpos anti-cxcr4 humanizados para el tratamiento del cáncer
EA201500261A1 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
CL2009000862A1 (es) Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer.
CL2007001711A1 (es) Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras.